<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="61475"><DrugName>PF-3049423</DrugName><DrugSynonyms><Name><Value>PF-3049423</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PF-03049423</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18767">Pfizer Inc</CompanyOriginator><CompaniesSecondary><Company id="18767">Pfizer Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="61475" type="Drug"><TargetEntity id="686172" type="siDrug">PF-3049423</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="677" type="ciIndication"><TargetEntity id="D009422" type="MeSH"></TargetEntity><TargetEntity id="-482975406" type="omicsDisease"></TargetEntity><TargetEntity id="82" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="65">Stroke</Indication><Indication id="677">Neurological disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="778">PDE 5 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-27T09:54:05.000Z</LastModificationDate><ChangeDateLast>2016-08-10T00:00:00.000Z</ChangeDateLast><AddedDate>2008-10-07T15:20:22.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt; was developing PF-3049423 (PF-03049423), a PDE5 inhibitor,  for the potential oral tablet treatment of neurological disorders, specifically stroke recovery [&lt;ulink linkID="947491" linkType="Reference"&gt;947491&lt;/ulink&gt;]. In December 2010, a phase II trial in ischemic stroke was initiated, which was terminated in November 2013 [&lt;ulink linkID="1161471" linkType="Reference"&gt;1161471&lt;/ulink&gt;] and, in February 2014, Pfizer listed the drug as discontinued from development [&lt;ulink linkID="1530384" linkType="Reference"&gt;1530384&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound had previously been discontinued from development for neurological disorders in March 2009 [&lt;ulink linkID="997850" linkType="Reference"&gt;997850&lt;/ulink&gt;]; however, it was listed as back in phase I development for neurological disorders in January 2010 [&lt;ulink linkID="1071193" linkType="Reference"&gt;1071193&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2010, a randomized, double blind, placebo controlled, phase II trial (&lt;ulink linkID="70627" linkType="Protocol"&gt;NCT01208233&lt;/ulink&gt;; A9541004) was initiated to evaluate the safety and tolerability of PF-3049423 therapy (1 - 6 mg daily for 90 days), initiated within 72 h of ischemic stroke (expected n = 240),  in the US and Korea. At that time,  trial completion was expected in September 2012. By April 2011, recruitment had also been initiated at sites in Europe, by October 2011, in Canada   and, by January 2013, in Taiwan and India. In  August 2013, trial completion was expected in April 2014. However, the trial was terminated in November 2013 (after enrollment of 181 subjects) as an interim analysis had demonstrated futility; there were no signals of serious safety concern   [&lt;ulink linkID="1161471" linkType="Reference"&gt;1161471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In December 2009, a randomized, double-blind, placebo-controlled, phase I study (&lt;ulink linkID="68159" linkType="Protocol"&gt;NCT01161069&lt;/ulink&gt;; A9541002), initiated in August 2009, had been completed in healthy volunteers (n = 48) in Belgium. The  study was designed to  assess the safety and pharmacokinetics of PF-3049423 [&lt;ulink linkID="1116605" linkType="Reference"&gt;1116605&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1530384" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1530384" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1530384" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="677">Neurological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1530384" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1530384" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1530384" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1530384" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="677">Neurological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1530384" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="677">Neurological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-12T00:00:00.000Z</StatusDate><Source id="1116605" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="677">Neurological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-30T00:00:00.000Z</StatusDate><Source id="947491" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-01-31T00:00:00.000Z</StatusDate><Source id="1161471" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-01-31T00:00:00.000Z</StatusDate><Source id="1161471" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1161471" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-10-31T00:00:00.000Z</StatusDate><Source id="1161471" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-04-30T00:00:00.000Z</StatusDate><Source id="1161471" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1161471" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01526"><Name>PDE 5</Name><SwissprotNumbers><Swissprot>P91119</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>